FDA Brief

Warning letters Drugs

FDA warning letter to

Pushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi

High riskIssued Jun 16, 2025Posted Jun 24, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Turkish OTC drug wipe maker Pushclean over missing finished-product and component testing.

What happened

FDA reviewed records Pushclean submitted after a September 4, 2024 request for records under section 704(a)(4). The review found the firm did not show finished-product identity and strength testing before release, did not show identity testing of incoming components, and did not show conductivity or total organic carbon testing on a component used to make the drugs. FDA also said the quality unit did not adequately oversee manufacturing and stability.

What FDA found

  1. The firm did not test each finished drug batch for identity and strength of the active ingredient before release.

    21 CFR 211.165(a)
  2. The firm did not test incoming components for identity and required purity, strength, and quality, and did not run conductivity and total organic carbon tests on a manufacturing component.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The quality unit lacked the authority or did not effectively use it to approve or reject components, containers, closures, in-process materials, packaging, labeling, and drug products.

    21 CFR 211.22(a)

What FDA wants

FDA tells Pushclean to correct the violations promptly and respond in writing within 15 working days; if it cannot finish, it must give reasons and a schedule. FDA also recommends a qualified CGMP consultant and a six-system audit if the firm resumes U.S. drug manufacturing.

Who should pay attention

  • U.S. importers and retailers of OTC drug wipes
  • brands that use this contract manufacturer
  • other OTC drug wipe makers sourcing from Turkey

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk